CLCM
AKRO

Crawford Lake Capital Management’s Akero Therapeutics AKRO Stock Holding History

Crawford Lake Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-43,826
Closed -$1.35M – 51
2020
Q3 		$1.35M Buy
+43,826
New +$1.53M 0.56% 46

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Crawford Lake Capital Management's AKRO Position: Q4 2020 in Review

Crawford Lake Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2020, closing a stake of 43,826 shares — an estimated $1.35M sold.

Crawford Lake Capital Management first reported a position in AKRO in Q3 2020 and held it in 1 quarter. The position peaked at $1.35M in Q3 2020. 94 funds tracked by Wall St. Rank hold AKRO as of Q4 2020.

  • Crawford Lake Capital Management reported no remaining Akero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Crawford Lake Capital Management sold 43,826 Akero Therapeutics shares in Q4 2020, an estimated $1.35M.
  • Crawford Lake Capital Management first reported a position in Akero Therapeutics in Q3 2020 and held it in 1 quarter.
  • Crawford Lake Capital Management's Akero Therapeutics position peaked at $1.35M in Q3 2020.
  • 94 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2020.

Based on Crawford Lake Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.